de Wit R, Reiss P, Bakker P J, Lange J M, Danner S A, Veenhof K H
Division of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands.
AIDS. 1989 Dec;3(12):847-50. doi: 10.1097/00002030-198912000-00011.
The efficacy of zidovudine (AZT) for treatment of patients with Kaposi's sarcoma as the initial manifestation of AIDS was determined in a non-randomized, phase-II clinical trial. Twenty-two patients were treated with zidovudine (300 mg 4 times daily for 8 weeks). In patients with stable disease or showing a response, treatment was continued. After 12 weeks the total daily dose was changed to 1000 mg. Only two of all 22 evaluable patients achieved a response (one complete and one partial response), of only brief duration (2 and 4 months, respectively). There was no such association between antiretroviral activity, increase in CD4+ cells and tumour response, as was reported during treatment with human recombinant interferon alpha (IFN-alpha). These findings do not support the use of zidovudine as a first-line treatment for patients with AIDS-associated Kaposi's sarcoma.
在一项非随机的II期临床试验中，确定了齐多夫定（AZT）对以卡波西肉瘤为艾滋病初始表现患者的治疗效果。22例患者接受齐多夫定治疗（每日4次，每次300 mg，共8周）。病情稳定或有反应的患者继续接受治疗。12周后，每日总剂量改为1000 mg。在所有22例可评估患者中，只有2例有反应（1例完全缓解，1例部分缓解），且持续时间短暂（分别为2个月和4个月）。与重组人α干扰素（IFN-α）治疗期间所报道的情况不同，抗逆转录病毒活性、CD4 +细胞增加与肿瘤反应之间不存在这种关联。这些发现不支持将齐多夫定用作艾滋病相关卡波西肉瘤患者的一线治疗药物。
